A couple of Australia’s most popular ASX 200 tech stocks are in the spotlight on Monday.
They are both charging higher in morning trade after the release of positive announcements.
Here’s what you need to know:
Nextdc Ltd (ASX: NXT)
The NextDC share price is up almost 5% to $14.21 on Monday after the data centre operator released an update on its contracted utilisation.
According to the release, following recent customer contract wins, NextDC’s pro forma contracted utilisation has increased by 71MW or 29% since 30 June to 316MW.
As a result of these customer contract wins, the ASX 200 tech stock pro-forma forward order book has increased by 53% to 205MW since 30 June.
Management notes that the pro-forma forward order book is expected to progressively convert to billings and revenue over the period FY 2026 to FY 2029.
In addition, the company provided an update on its FY 2026 capital expenditure guidance.
It revealed that its guidance has been increased by $400 million as it accelerates a proportion of its planned inventory expansion, with the additional capex required to build and deploy capacity for the new customer contracts:
This has seen its capital expenditure guidance lift to the range of $2,200 million to $2,400 million from $1,800 million to $2,000 million.
Its FY 2026 net revenue and underlying EBITDA guidance remain unchanged.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price is up 2.5% to $272.85 after the health imaging technology provider announced another new contract win.
Pro Medicus’ U.S. subsidiary, Visage Imaging, has signed an additional $25 million, seven-year contract with BayCare. It is the leading health care system in the Tampa Bay and central Florida regions of the United States.
The contract will add the ASX 200 tech stock’s cloud-based Visage 7 Open Archive to the existing Visage 7 Viewer and Visage 7 Workflow contract signed in February 2025. This will provide BayCare with a full stack solution that is targeted to go-live in first quarter of calendar year 2026.
Commenting on the contract win, Pro Medicus CEO’s, Dr Sam Hupert, said:
This deal confirms our belief that there is a material opportunity for us to sell Visage 7 Open Archive to new and existing customers such as BayCare. In doing so, we not only enable them to fully transition their on-premise infrastructure to cloud, we provide them with the most performant, scalable and cost-effective archive solution.
The post 2 ASX 200 tech stocks racing higher on big news appeared first on The Motley Fool Australia.
Should you invest $1,000 in NEXTDC Limited right now?
Before you buy NEXTDC Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and NEXTDC Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 18 November 2025
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- ASX 200 tech shares fight back after 10 weeks of decline
- 3 ASX growth shares that could be future giants
- 5 ASX 200 large-cap shares re-rated by Morgans
- The unstoppable ASX stocks powering the AI revolution
- Macquarie reveals ASX 200 share tips in each market sector for 2026
Motley Fool contributor James Mickleboro has positions in Nextdc and Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
Leave a Reply